News
MHRA authorises UCB’s Bimzelx via post-Brexit licensing pathway
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved UCB’s Bimzelx (bimekizumab) for the treatment of adults with moderate to severe plaque psoriasis.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved UCB’s Bimzelx (bimekizumab) for the treatment of adults with moderate to severe plaque psoriasis.